Cargando…

Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)

Our recent study revealed that non-neuroendocrine small cell lung cancer (SCLC) is sensitive to the induction of ferroptosis due to upregulation of ether lipid synthesis. While neuroendocrine SCLC is ferroptosis resistant, it acquires addiction to the thioredoxin pathway. Combined redox pathway targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bebber, Christina M., von Karstedt, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489942/
https://www.ncbi.nlm.nih.gov/pubmed/34616869
http://dx.doi.org/10.1080/23723556.2021.1933871
_version_ 1784578425899450368
author Bebber, Christina M.
von Karstedt, Silvia
author_facet Bebber, Christina M.
von Karstedt, Silvia
author_sort Bebber, Christina M.
collection PubMed
description Our recent study revealed that non-neuroendocrine small cell lung cancer (SCLC) is sensitive to the induction of ferroptosis due to upregulation of ether lipid synthesis. While neuroendocrine SCLC is ferroptosis resistant, it acquires addiction to the thioredoxin pathway. Combined redox pathway targeting therefore achieves efficient anti-tumor activity in heterogenous SCLC.
format Online
Article
Text
id pubmed-8489942
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84899422021-10-05 Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC) Bebber, Christina M. von Karstedt, Silvia Mol Cell Oncol Author’s Views Our recent study revealed that non-neuroendocrine small cell lung cancer (SCLC) is sensitive to the induction of ferroptosis due to upregulation of ether lipid synthesis. While neuroendocrine SCLC is ferroptosis resistant, it acquires addiction to the thioredoxin pathway. Combined redox pathway targeting therefore achieves efficient anti-tumor activity in heterogenous SCLC. Taylor & Francis 2021-07-05 /pmc/articles/PMC8489942/ /pubmed/34616869 http://dx.doi.org/10.1080/23723556.2021.1933871 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Bebber, Christina M.
von Karstedt, Silvia
Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title_full Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title_fullStr Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title_full_unstemmed Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title_short Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
title_sort non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (sclc)
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489942/
https://www.ncbi.nlm.nih.gov/pubmed/34616869
http://dx.doi.org/10.1080/23723556.2021.1933871
work_keys_str_mv AT bebberchristinam nonneuroendocrinedifferentiationgeneratesaferroptosispronelipidomeinsmallcelllungcancersclc
AT vonkarstedtsilvia nonneuroendocrinedifferentiationgeneratesaferroptosispronelipidomeinsmallcelllungcancersclc